Academic, foundation, and industry collaboration in finding new therapies

New England Journal of Medicine

Volumn 376, Issue 18, 2017, Pages 1762-1769

  Ramsey, Bonnie W ^a,b   Nepom, Gerald T ^c,d   Lonial, Sagar ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c Immune Tolerance Network   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DEXAMETHASONE; ELOTUZUMAB; GANETESPIB; INTERLEUKIN 2; IVACAFTOR; IVACAFTOR PLUS LUMACAFTOR; LENALIDOMIDE; POMALIDOMIDE;

CFTR GENE; CYSTIC FIBROSIS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; EXPERIMENTAL THERAPY; GENE REPLACEMENT THERAPY; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INTERSECTORAL COLLABORATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; COOPERATION; DIABETES MELLITUS, TYPE 1; DRUG INDUSTRY; GOVERNMENT; NON PROFIT ORGANIZATION; PUBLIC-PRIVATE PARTNERSHIP; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; COOPERATIVE BEHAVIOR; CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 1; DRUG INDUSTRY; FOUNDATIONS; GOVERNMENT AGENCIES; HUMANS; MULTIPLE MYELOMA; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 85019094414     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1612575     Document Type: Review

References (42)

1. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337: 816-21.
2. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-23.
3. Green ED, Watson JD, Collins FS. Human Genome Project: Twenty-five years of big biology. Nature 2015; 526: 29-31.
4. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-99.
5. Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373: 1783-4.
6. Collins FS. Reengineering translational science: The time is right. Sci Transl Med 2011; 3: 90cm17.
7. Butler D. Translational research: Crossing the valley of death. Nature 2008; 453: 840-2.
8. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363: 301-4.
9. Hanson S, Nadig L, Altevogt B, eds. Venture philanthropy strategies to support translational research: Workshop summary. Washington, DC: National Academies Press, 2009.
10. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: Genetic analysis. Science 1989; 245: 1073-80.
11. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989; 245: 1066-73.
12. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77: 701-26.
13. Cystic Fibrosis Mutation Database. 2011 (http://www .genet .sickkids .on .ca/app).
14. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-4.
15. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992; 2: 21-5.
16. Harvey BG, Leopold PL, Hackett NR, et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999; 104: 1245-55.
17. Welsh MJ. Gene transfer for cystic fibrosis. J Clin Invest 1999; 104: 1165-6.
18. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009; 8: 153-71.
19. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1117-30.
20. Higgins RF, LaMontagne S, Kazan B. Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture philanthropy funding for biotech. Harvard Business School Case 808-005, October 2007 (http://www .hbs .edu/faculty/Pages/item .aspx?num=35037). (Revised July 2013.)
21. Ashlock MA, Olson ER. Therapeutics development for cystic fibrosis: A successful model for a multisystem genetic disease. Annu Rev Med 2011; 62: 107-25.
22. Rowe SM, Borowitz DS, Burns JL, et al. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax 2012; 67: 882-90.
23. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-72.
24. Check Hayden E. Promising gene therapies pose million-dollar conundrum. Nature 2016; 534: 305-6.
25. Ferkol T, Quinton P. Precision medicine: At what price? Am J Respir Crit Care Med 2015; 192: 658-9.
26. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-25.
27. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study. Blood 2014; 123: 1826-32.
28. Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30: 1953-9.
29. Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30: 1960-5.
30. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
31. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-81.
32. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-72.
33. Kowalski J, Dwivedi B, Newman S, et al. Gene integrated set profile analysis: A context-based approach for inferring biological endpoints. Nucleic Acids Res 2016; 44(7): E69.
34. Eisenbarth GS. Type I diabetes mellitus. N Engl J Med 1986; 314: 1360-8.
35. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs ß-cell function. Diabetes 2012; 61: 2340-8.
36. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin- 2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002; 51: 638-45.
37. Long SA, Buckner JH, Greenbaum CJ. IL-2 therapy in type 1 diabetes: "trials" and tribulations. Clin Immunol 2013; 149: 324-31.
38. Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 2015; 125: 3285-96.
39. Pinckney A, Rigby MR, Keyes-Elstein L, Soppe CL, Nepom GT, Ehlers MR. Correlation among hypoglycemia, glycemic variability, and c-peptide preservation after alefacept therapy in patients with type 1 diabetes mellitus: Analysis of data from the Immune Tolerance Network T1DAL trial. Clin Ther 2016; 38: 1327-39.
40. Buckner JH, Nepom GT. Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. J Autoimmun 2016; 71: 44-50.
41. Bluestone JA, Crellin N, Trotta E. IL-2: Change structure . . . change function. Immunity 2015; 42: 779-81.
42. Gill RG, Pagni PP, Kupfer T, et al. A preclinical consortium approach for assessing the efficacy of combined anti- CD3 plus IL-1 blockade in reversing newonset autoimmune diabetes in NOD mice. Diabetes 2016; 65: 1310-6.